Willis Paul
AstraZeneca
21 Papers
455 Citations
Willis Paul is an academic researcher from AstraZeneca. The author has contributed to research in topics: Alkyl & Isoquinoline. The author has an hindex of 10, co-authored 21 publications. Previous affiliations of Willis Paul include The Hertz Corporation.
Chat about Author
Papers
Patent
Novel thiazolo(4,5-d)pyrimidine compounds
Willis Paul,Roger Bonnert,Iain Walters +2 more
- 02 Dec 1999
TL;DR: In this paper, the authors provide a list of thiazolopyrimidine compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof; processes and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy.
142
Patent
Triazolo(4,5-d)pyrimidine compounds
David Hardern,Anthony Ingall,Brian Springthorpe,Willis Paul,Simon Guile +4 more
- 02 Dec 1999
TL;DR: Triazolo as mentioned in this paper described the use of pyrimidine compounds as medicaments, compositions containing them and processes for their preparation, and the formulas of the pyrimidines.
56
Patent
Novel thiazolopyrimidine compounds
Austin Rupert,Baxter Andrew,Bonnert Roger,Fraser Hunt,Kinchin Elizabeth,Willis Paul +5 more
- 03 Aug 1999
TL;DR: In this article, the authors describe processes and intermediates used in the preparation of thiazolopyrimidine compounds of general formula (I), pharmaceutical compositions containing them and their use in therapy.
47
Patent
Inhibitors of platelet aggregation
Cox David,Ingall Anthony,Willis Paul +2 more
- 04 Jul 1996
TL;DR: In this article, the authors proposed a novel compound for platelet aggregation, which is useful in the prevention of platelet aggregates, and used it in the treatment of cancer.
33
Patent
Triazolo(4,5-d)pyrimidinyl derivatives and their use as medicaments
Roger Bonnert,Anthony Ingall,Brian Springthorpe,Willis Paul +3 more
- 12 Dec 1997
TL;DR: The triazolo[4,5-d]pyrimidin-3-yl derivatives of formula (I) were used in the treatment of platelet aggregation disorders as mentioned in this paper.
31